Abstract Background For centuries, American indigenous populations have utilized psilocybin-containing mushrooms for both traditional medical and religious purposes, often in the context of psychedelic experiences. More recently, there has been a notable increase in the interest for and in the practice of psilocybin 'microdosing': regular intake of psilocybin-containing mushrooms in amounts...
Abstract Background Pain is a major health problem resulting in a high degree of suffering, physical, psychological and social impairments, and exorbitant health care costs1-2. Effective pain treatments are limited and are often accompanied by significant side effects3. Preclinical and clinical studies suggest that psychedelics, specifically psilocybin, can reset brain areas of functional...
Abstract Major Depressive Disorder (MDD) is a highly prevalent mental health condition characterized by symptoms including anhedonia, which is defined as diminished pleasure, and impulsivity, which has been linked to increased substance abuse, self-harm and suicidal tendencies. Both anhedonia and impulsivity have been contributed to alterations in reward system function, with the striatum being...
Psilocybin (a psychoactive compound found in "magic mushrooms" or "shrooms") has been gaining increased attention in research and popular culture as a number of clinical and observational studies have demonstrated that it may have potential for improving mental wellbeing. Relatedly, there has been a substantial uptick in naturalistic (e.g., real-world, non-clinical) psilocybin use in the United...
Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of...
• A 60-year-old man with recurrent depression and history of delusions died after psilocybin-assisted therapy. • Psilocybin-triggered delusions and emotional dysregulation may have contributed. • Weak therapeutic alliance hindered assessment of patient's internal state. • Delusional symptoms may contraindicate psychedelic interventions. • This case emphasizes the need for thorough assessment...
New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and license psilocybin facilitators. This study describes Oregon's early psilocybin facilitator workforce and assesses state-approved training programs. The Open Psychedelic Evaluation Nexus (OPEN) reviewed Oregon Health Authority-approved training programs and surveyed...
This study's results are expected to offer critical insights into the neural mechanisms underlying the effects of psilocybin-assisted therapy in treating OCD, and whether these correlate with changes in the cognitive features of the condition. As a secondary aim, it will ascertain whether a low, tolerable dose is a feasible and efficacious clinical treatment, and will provide crucial data to...
Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocybin-assisted therapy training is crucial, as it can affect treatment safety, effectiveness and accessibility. As such, the ethical and practical issues associated with such a training standard require timely consideration in jurisdictions where this...
Background: Psilocybin is a natural alkaloid with therapeutic potential in the treatment of different mental disorders. Bibliometric information on its use is still scattered in the literature. Objective: To investigate the temporal and bibliometric patterns of publications and the specificity of psilocybin in the treatment of mental disorders. Method: Performed a bibliometric analysis using...